A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC).

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and ...

Douglas Hanahan (left), the former Director of the Swiss Institute for Experimental Cancer Research (ISREC) at EPFL, works in the Agora Translational Cancer Research Center as a member of the Ludwig ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...